Raymond Joseph Ippolito, MD | |
420 East Main Street, Bldg 2 Unit 5, Branford, CT 06405 | |
(203) 481-6722 | |
(203) 483-2074 |
Full Name | Raymond Joseph Ippolito |
---|---|
Gender | Male |
Speciality | Surgery |
Location | 420 East Main Street, Branford, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487752903 | NPI | - | NPPES |
709727 | Other | CONNECTICARE | |
010016865CT01 | Other | BCBS | |
0Q1189 | Other | HEALTHNET |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 016865 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Raymond Joseph Ippolito, MD 420 East Main Street, Bldg 2 Unit 5, Branford, CT 06405 Ph: (203) 481-6722 | Raymond Joseph Ippolito, MD 420 East Main Street, Bldg 2 Unit 5, Branford, CT 06405 Ph: (203) 481-6722 |
News Archive
As part of its efforts to reverse the opioid crisis that continues to grip the nation, the National Institutes of Health has named McLean Hospital as a recipient of a grant through the Helping to End Addiction Long-term Initiative (NIH HEAL Initiative).
A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient survival rates, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
The new Urban Dynamics Institute at the Department of Energy's Oak Ridge National Laboratory is working with the Bill & Melinda Gates Foundation to aid polio vaccination efforts in developing countries.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company's New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.
› Verified 1 days ago